A sensitive, high-throughput, immunocapture-based assay for direct quantification of Lp(a)-cholesterol (Lp(a)-C) has been validated for potential use in research studies and clinical trials. The assay uses an apo(a)-specific mAb (LPA4) coupled to magnetic beads to quantify Lp(a)-C in human plasma.
